WYE-687 explained

WYE-687 is a drug which acts as an inhibitor of both subtypes of the mechanistic target of rapamycin (mTOR), mTORC1 and mTORC2. It is being researched for potential applications in the treatment of various forms of cancer.[1] [2] [3]

Notes and References

  1. Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, Cole DC, Ellingboe J, Ayral-Kaloustian S, Mansour TS, Gibbons JJ, Abraham RT, Nowak P, Zask A . 6 . Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin . Cancer Research . 69 . 15 . 6232–40 . August 2009 . 19584280 . 10.1158/0008-5472.CAN-09-0299 . free .
  2. Cheng F, Wang L, Shen Y, Xia J, Chen H, Jiang Y, Lu M . Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent . Biochemical and Biophysical Research Communications . 470 . 2 . 324–330 . February 2016 . 26792718 . 10.1016/j.bbrc.2016.01.054 .
  3. Pan XD, Gu DH, Mao JH, Zhu H, Chen X, Zheng B, Shan Y . Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo . PLOS ONE . 2017 . 12 . 3 . e0172555 . 28257457 . 10.1371/journal.pone.0172555 . 5336203 . 2017PLoSO..1272555P . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "WYE-687".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.